3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Myeloid
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Magnetic Resonance Spectroscopy
63
Specimen Handling
58
pembrolizumab
40
enzalutamide
38
Nivolumab
32
Gemcitabine
30
Docetaxel
28
Biopsy
25
Prednisone
23
Abiraterone Acetate
21
apalutamide
20
Androgen Antagonists
19
Radiosurgery
18
Cisplatin
18
darolutamide
16
cabozantinib
16
abiraterone
16
Radiotherapy
16
enfortumab vedotin
15
Radiation
14
Ipilimumab
13
belzutifan
12
Pluvicto
12
Mitomycin
12
olaparib
11
erdafitinib
11
durvalumab
11
atezolizumab
11
X-Rays
10
Standard of Care
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Blood Component Removal
×
Genitourinary
×
30 days
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled